Table 1.
Influence of circulating tumour cell (CTC) count on non-small-cell lung cancer (NSCLC) chemotherapy.
| Patient Characteristics | Clinical Finding | Ref. |
|---|---|---|
| 101 patients with stage IIIA, IIIB, or IV disease; platinum doublet chemotherapy (United Kingdom) | CTC count 1 for prediction 2 (baseline): ≥5; PFS (6.8 vs. 2.4) and OS (8.1 vs. 4.3) | [17] |
| CTC count for prediction (after therapy): ≥5; PFS (7.6 vs. 2.4) and OS (8.8 vs. 4.3) | ||
| 21 patients with stage IV disease; previous chemotherapy with belagenpumatucel-L, 16 months (USA) | CTC count for prediction: ≥2; OS (20 vs. 5) | [27] |
| 37 patients with stage IIIB disease with pleural effusion or stage IV disease with bidimensionally measurable lesions in a previously irradiated field; docetaxel plus gemcitabine, 28 days 4 (Spain) | CTC distribution: ≥1 (58%) 3, ≥2 (32%), and ≥5 (8%) | [31] |
| CTC count for prediction (baseline): ≥2 (nonsignificant); OS (8.1 vs. 12.2) and PFS (9.4 vs. 4.3) | ||
| CTC count for prediction (after therapy): ≤ 1; OS (10.1 vs. X 5) | ||
| 46 patients with stage IIIB or IV disesease; platinum doublet therapy (China) | CTC distribution: ≥1 (87), ≥3 (63), ≥5 (37) and ≥8 (15) | [28] |
| CTC count for prediction (baseline): ≥8; (OS (21.3 vs. 9.0) and PFS (7.4 vs. 5.3)) |
1 The CTC counts discussed in this table were determined with CellSearch and with 7.5 mL of blood. 2 Overall survival (OS) and progression-free survival (PFS) shown in months. 3 Proportion of patients with a given number of CTCs. 4 Length of chemotherapy. 5 Study time too short for determination.